The abstract is read at the publisher; the summary is JClub's.
High folate receptor α (FOLR1) expression in colorectal cancer is linked to poor immune checkpoint blockade response and is associated with impaired CD8+ T cell infiltration and cytotoxicity.
- Why it matters: CRC immune evasion via reduced MHC-I presentation limits immune checkpoint blockade, so new targets are needed to restore effective antitumor immunity.
- What they did: Using fluorescence-activated cell sorting–based CRISPR activation screens with a druggable genome library, the study identified FOLR1 as a negative regulator, then tested mirvetuximab soravtansine (IMGN853) alone and with anti-PD-1 in vivo.
- The result: The anti-FOLR1 ADC reprogrammed the tumor microenvironment to an immune-active state and, combined with anti-PD-1, sensitized tumors and induced robust tumor regression in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.